Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
NCT03719768Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2019
- Primary completion
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avelumab in leptomeningeal disease (LMD), sponsored by Moffitt Cancer Center. Primary endpoint: Safety and Dose Limiting Toxicity at 3 months. Started Jun 2019; status: completed.
02
Drugs
avelumab
03
Conditions
leptomeningeal disease (LMD)
Beyond the preview
Go deeper on NCT03719768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719768.